Endogena Therapeutics

Executive Summary

Endogena Therapeutics is a Swiss biotechnology company pioneering endogenous regenerative medicine to address degenerative diseases, with a primary focus on ophthalmology. Leveraging the body's own regenerative capacity, the company's platform aims to restore tissue function by activating endogenous stem cells or progenitor cells. This approach offers a paradigm shift from symptomatic treatments to disease-modifying therapies, targeting conditions such as retinitis pigmentosa and age-related macular degeneration, which are increasingly prevalent due to aging populations. Founded in 2013 and headquartered in Basel, Endogena has advanced its lead candidate into Phase 1/2 clinical trials, representing a significant milestone in validating its platform.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim safety and efficacy data readout45% success
• Q4 2026Potential strategic partnership for lead program30% success
• Q2 2026Preclinical data for second indication or next-generation candidate50% success